Evidence map›Paper›PMID 42681408›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Mouse Model of Hemolytic Disease of the Fetus and Newborn.

Hirotomo Nakahara, Sasikala Muthusamy, Rebecca C Hale, Brock D Hughes, Sean R Stowell

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hirotomo NakaharaDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA. hnakahara@bwh.harvard.edu.
Sasikala MuthusamyDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Rebecca C HaleDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Brock D HughesDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sean R StowellDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA. srstowell@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemolytic Disease of the Fetus and Newborn (HDFN) is caused by the placental transfer of maternal red blood cell (RBC) alloantibodies into the fetal circulation which then targets paternally derived RBC antigens expressed on the fetal RBC. The resulting anemia in the fetus/newborn can lead to grave clinical consequences including hydrops fetalis, kernicterus, and perinatal demise. We have utilized the human KEL transgenic mouse model to study the induction of anti-KEL RBC alloantibodies through pregnancy as well as transfusion and the subsequent placental transfer of anti-KEL RBC alloantibodies into the fetal circulation, causing anemia, hydrops, and fetal/neonatal demise. Here, we describe the methods used to establish the KEL transgenic mouse HDFN model and the assays that evaluate the key pathologic features of HDFN.

Indexed as

Erythroblastosis, FetalKell Blood-Group SystemAnimalsAnimals, NewbornDisease Models, AnimalErythrocytesFemaleHumansIsoantibodiesMiceMice, TransgenicPregnancyIsoantibodiesKell Blood-Group SystemAnemiaHDFNHemolytic Disease of the Fetus and NewbornKELKellPregnancyRBC alloantibodyRBC alloimmunizationTransfusion

Identifiers

PMID42681408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.